$1.03
2.83% day before yesterday
Nasdaq, Dec 27, 10:10 pm CET
ISIN
US47010C3007
Symbol
JAGX
Sector
Industry

Jaguar Health, Inc. Stock price

$1.03
+0.03 3.51% 1M
-2.59 71.55% 6M
-8.05 88.66% YTD
-8.75 89.47% 1Y
-5,083.97 99.98% 3Y
-9,019.67 99.99% 5Y
-96,106,498.97 100.00% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.03 2.83%
ISIN
US47010C3007
Symbol
JAGX
Sector
Industry

Key metrics

Market capitalization $9.52m
Enterprise Value $32.50m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 3.10
P/S ratio (TTM) P/S ratio 0.91
P/B ratio (TTM) P/B ratio 0.79
Revenue growth (TTM) Revenue growth -2.25%
Revenue (TTM) Revenue $10.48m
EBIT (operating result TTM) EBIT $-29.86m
Cash position $13.27m
EPS (TTM) EPS $-16.10
P/E forward negative
P/S forward 0.84
EV/Sales forward 2.88
Short interest 3.60%
Show more

Is Jaguar Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Jaguar Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Jaguar Health, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Jaguar Health, Inc.:

Buy
100%

Financial data from Jaguar Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
10 10
2% 2%
100%
- Direct Costs 4.44 4.44
22% 22%
42%
6.04 6.04
15% 15%
58%
- Selling and Administrative Expenses 18 18
1% 1%
172%
- Research and Development Expense 15 15
20% 20%
148%
-28 -28
10% 10%
-262%
- Depreciation and Amortization 2.36 2.36
2% 2%
23%
EBIT (Operating Income) EBIT -30 -30
10% 10%
-285%
Net Profit -38 -38
5% 5%
-360%

In millions USD.

Don't miss a Thing! We will send you all news about Jaguar Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Jaguar Health, Inc. Stock News

Neutral
Accesswire
10 days ago
Magdalena to explore coca leaf's possible therapeutic benefit for treatment of potentially ADHD or other neuropsychiatric indications The import was conducted in collaboration with the government of Peru Steven King, Ph.D. of Jaguar to speak about the potential promise of coca-based Botanical Drugs at the February 2025 Wisdom of the Leaf Coca Summit in Peru Magdalena is focused on developing no...
Neutral
Accesswire
11 days ago
The study is one of five clinical efforts - three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications of MVID and/or short bowel syndrome with intestinal failure (SBS-IF) in the US, EU, and/or Middle East/North Africa regions; availability of first IIT proof-of-concept results potentially in Q1 2025 Crofelemer, Jaguar's n...
Neutral
Accesswire
12 days ago
World Health Organization (WHO) has classified the global resurgence of cholera at the highest internal level for emergencies; 1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae Crofelemer previously granted orphan-drug designation by t...
More Jaguar Health, Inc. News

Company Profile

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Head office United States
CEO Lisa Conte
Employees 49
Founded 2013
Website www.jaguar.health

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today